Table 3. Second-line therapy after disease progression.
| Therapy | Maintenance therapy (n=47), n (%) | No maintenance therapy (n=29), n (%) |
|---|---|---|
| EGFR-TKI | 14 (29.8) | 2 (6.9) |
| Crizotinib | 3 (6.4) | 1 (3.4) |
| Docetaxel-based therapy | 15 (31.9) | 9 (31.0) |
| Radiotherapy | 3 (6.4) | 3 (10.3) |
| Other treatment | 6 (12.8) | 4 (13.8) |
| No treatment | 6 (12.8) | 10 (34.5) |
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.